Table 4 Comparison between our study and previous reports
Patients, n | female, % | Age at disease on set, mean(y) | lesions | Initial syptoms | Comorbidities | treatment | CNO family history,% | Immunological indicators | Follow up, mean(m) | |
|---|---|---|---|---|---|---|---|---|---|---|
China, Ma L. et al., (present study) | 18 | 56 | 9.2 | 94%:Mulifocal 6%:unifocal | 100%:Pain 22%:swelling 28%:limp 44%:Fever | 44.4%:Arthritis 5%:IBD 5%:skin lesions | 1st line NSAIDS 2nd line: Steroids SSZ, MTX, Bisphosphonates and TNF blockers | 0 | 0:HLA-B27 (+) 0:ANA (+) | 16 |
United states, Gaal A, et al., (2020) [21] | 22 | 36 | 11 | 18%:Multifocal 82%: Unifocal | ND | ND | 1st line NSAIDS 2ndline: Steroids, DMARDS, Bisphosphonates and TNF blockers | ND | 7%:HLA-B27(+) 30%:ANA (+) | ND |
Chile, Concha S, et al. (2020) [19] | 19 | 47 | 10 | 100%:Multifacal | ND | 21%:Arthritis 0:IBD 0:skin lesions | 1st line NSAIDS 2nd line: Steroids MTX, Bisphosphonates and TNF blockers (adalimumab) | ND | 16%:HLA-B27(+) 37%:ANA (+) | ND |
India, Rao A, et al. (2018) [17] | 6 | 0 | 13 | 100%:Multifacal | 100%:pain 33%:fever | ND | 1st line: NSAID’S and Methotrexate 2nd line: Bisphosphonates/ TNF-blockers | ND | ND | 31.5 |
Europe, Girschick H, et al.(2018) [8] | 486 | 64 | 9.9 | 71%:Mulifocal 29%:unifocal | ND | 29%:Arthritis 8%:IBD 14%:skin lesions | 1st line NSAIDS 2nd line: Steroids SSZ, MTX, Bisphosphonates and TNF blockers | 3 | 8%:HLA-B27 (+) 38%:ANA (+) | 49 |
Germany Schnabel A, et al.,(2017) [20] | 56 | 59 | 11 | 77%:Multifocal 23%: Unifocal | 11%:fever | 36%:Arthritis 11%:IBD 18%:skin lesions | 1st line NSAIDS 2ndline: steroids, MTX, SSZ, Bisphosphonates, and TNF blockers | ND | 21%:HLA-B27(+) 15%:ANA (+) | 29 |
UK, Roderick MR, et al. (2016) [24] | 41 | 76 | 9 | 76%:Multifocal 26%: Unifocal | 15%:fever 17%:swelling | 10%:skin lesions | 1st line NSAIDS 2ndline: steroids, MTX, SSZ, Bisphosphonates, and TNF blockers | ND | ND | 96 |
Germany, Silier CCG, et al. (2015) [18] | 105 | 73 | 9.5 | 80%:Mulifocal 20%:unifocal | 97%:Pain 60%:swelling 25%:redness 17%:Fever | 9%:Arthritis 1%:IBD 19%:skin lesions | 1st line NSAIDS and steroids 2ndline:Bisphosphonates and TNF blockers | 15 | ND | ND |
France, Wipff J, et al. (2015) [12] | 178 | 69 | 9.8 | 70%:Mulifocal 30%:unifocal | 20%:fever | 11%:Arthritis 33%:IBD 8%:skin lesions | 1st line NSAIDS 2ndline: steroids, MTX, SSZ, Bisphosphonates, TNF blockers and anti–IL-1R (anakinra) | 32 | 7%:HLA-B27 (+) 12%:ANA (+) | 47 |
Australia, Walsh P, et al. (2015) [25] | 34 | 62 | 9.8 | 82%:Multifocal 18%: Unifocal | ND | 50%:Arthritis 3%:IBD, uveitis 36%:skin lesions | 1st line NSAIDS 2nd line: Steroids MTX, AZA, Adalimumab | ND | 9%:HLA-B27(+) 36%:ANA (+) | 25 |
Germany, Beck C, et al. (2010) [23] | 37 | 65 | 11 | 78%:Multifocal 22%: Unifocal | 37%:swelling 22%:morning stiffness | 38%:Arthritis 3%:IBD 17%:skin lesions | 1st line Naproxen 2nd line: Sulfasalazine and steroids | ND | 8%:HLA-B27(+) 59%:ANA (+) | 6 |
France, Catalano-Pons C, et al., (2008) [22] | 40 | 85 | 10 | 62%:Multifocal 38%: Unifocal | 100%:pain 10%:swelling 23%:fever | 10%:Arthritis 3%:skin lesions | 1st line NSAIDS 2ndline: Steroids, SSZ, MTX, AZA Bisphosphonates and TNF blockers (etanercept) | ND | ND | ND |
Germany, Jansson A, et al. (2007) [15] | 89 | 65 | 10 | 81%:Multifocal 19%: Unifocal | ND | 7%:IBD 25%:skin lesions | 1st line NSAIDS 2ndline: Steroids, MTX, AZA, Bisphosphonates and TNF blockers (Infliximab) | 12 | 0:HLA-B27(+) 33%:ANA (+) | ND |